Press release

DSM wins patent opposition appeal impacting stereolithography development

Elgin IL , US, 23 Jan 2014 17:00 CET

Royal DSM, the global Life Sciences and Materials Sciences Company, has won an appeal regarding the opposition of patent EP1232198, titled, UV Curable Compositions at the European Patent Office Board of Appeal in Munich, Germany on 17 January 2014. This patent, currently assigned to 3D Systems, Inc., was revoked at the European level, thus allowing for increased development of materials in this field.

We’re pleased with the outcome as it encourages innovation in the area of photopolymers for stereolithography. We continue to focus on delivering the best materials to fit the industry and our customers’ needs,” says Melissa Hayes, Somos® Business Director for DSM.

DSM is committed to moving the industry to new levels of performance with their Somos stereolithography materials, a distinct and unique subset of additive manufacturing. With over 20 years of industry experience, DSM offers a large portfolio of Somos products that fit a wide range of applications and is dedicated to the success of this industry for the future.

For more information

DSM Functional Materials

Kelly Hawkinson, Global Marketing & Communications Director

+1 847 608 2530

Read more

  • Our products

    DSM portfolio of innovative biomedical materials and process manufacturing technologies: Biomedical Polyethylenes, Biomedical polyurethanes, Collagen Technology, Device Development, and Extracellular Matrix (ECM) Technology. Learn more.

  • The markets we serve

    DSM Biomedical offers the broadest portfolio of biomedical materials and manufacturing across market applications, including orthopedics, ophthalmology, neurology, cardiology, diabetes, wound, and continence care.

This site uses cookies to store information on your computer.

Learn more